药械

订阅

MedSci主页 / 所有栏目 / 药械

默沙东眼部药物Zioptan获得FDA批准

2012-02-15 MedSci MedSci原创

ZioptanFDA
关注

默沙东周一表示，美国食品和药物管理局批准其Zioptan（tafluprost滴眼液）作为治疗某些种类青光眼的解决方案。 此药是第一个不含防腐剂的解决方案，以帮助减少与开角型青光眼或高眼压症患者眼压增高。开角型青光眼是青光眼最常见的形式，高眼压是在眼内压力增加为主要特征。 默沙东副总裁大卫迈克尔逊说：“我们很高兴能够继续默沙东在神经病学和眼科治疗领域的长达50年的传统，帮助满足眼睛护理

默沙东周一表示，美国食品和药物管理局批准其Zioptan（tafluprost滴眼液）作为治疗某些种类青光眼的解决方案。

此药是第一个不含防腐剂的解决方案，以帮助减少与开角型青光眼或高眼压症患者眼压增高。开角型青光眼是青光眼最常见的形式，高眼压是在眼内压力增加为主要特征。

默沙东副总裁大卫迈克尔逊说：“我们很高兴能够继续默沙东在神经病学和眼科治疗领域的长达50年的传统，帮助满足眼睛护理专业人士和患者的需求。”

默沙东预计Zioptan下个月可提供给患者，售价97美元。

在下午的交易中，默沙东的股价上涨了17美分，至38.08美元每股。

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=11580, encodeId=250a115803e, content=非常有帮助，谢谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bc892015, createdName=sweetai, createdTime=Mon Sep 08 23:15:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839135, encodeId=3f6f183913593, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:16:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776038, encodeId=6d5b1e76038e6, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Apr 06 22:16:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707512, encodeId=ad411e0751266, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed Mar 28 12:16:00 CST 2012, time=2012-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259877, encodeId=127f12598e748, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Fri Feb 17 14:16:00 CST 2012, time=2012-02-17, status=1, ipAttribution=)]
    2014-09-08 sweetai

    非常有帮助，谢谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=11580, encodeId=250a115803e, content=非常有帮助，谢谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bc892015, createdName=sweetai, createdTime=Mon Sep 08 23:15:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839135, encodeId=3f6f183913593, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:16:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776038, encodeId=6d5b1e76038e6, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Apr 06 22:16:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707512, encodeId=ad411e0751266, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed Mar 28 12:16:00 CST 2012, time=2012-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259877, encodeId=127f12598e748, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Fri Feb 17 14:16:00 CST 2012, time=2012-02-17, status=1, ipAttribution=)]
    2012-03-02 zhaojie88

    #FDA批准#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=11580, encodeId=250a115803e, content=非常有帮助，谢谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bc892015, createdName=sweetai, createdTime=Mon Sep 08 23:15:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839135, encodeId=3f6f183913593, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:16:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776038, encodeId=6d5b1e76038e6, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Apr 06 22:16:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707512, encodeId=ad411e0751266, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed Mar 28 12:16:00 CST 2012, time=2012-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259877, encodeId=127f12598e748, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Fri Feb 17 14:16:00 CST 2012, time=2012-02-17, status=1, ipAttribution=)]
    2012-04-06 huiwelcome

    #眼部#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=11580, encodeId=250a115803e, content=非常有帮助，谢谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bc892015, createdName=sweetai, createdTime=Mon Sep 08 23:15:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839135, encodeId=3f6f183913593, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:16:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776038, encodeId=6d5b1e76038e6, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Apr 06 22:16:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707512, encodeId=ad411e0751266, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed Mar 28 12:16:00 CST 2012, time=2012-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259877, encodeId=127f12598e748, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Fri Feb 17 14:16:00 CST 2012, time=2012-02-17, status=1, ipAttribution=)]
    2012-03-28 124987c6m46暂无昵称

    #IOP#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=11580, encodeId=250a115803e, content=非常有帮助，谢谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bc892015, createdName=sweetai, createdTime=Mon Sep 08 23:15:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839135, encodeId=3f6f183913593, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:16:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776038, encodeId=6d5b1e76038e6, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Apr 06 22:16:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707512, encodeId=ad411e0751266, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed Mar 28 12:16:00 CST 2012, time=2012-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259877, encodeId=127f12598e748, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Fri Feb 17 14:16:00 CST 2012, time=2012-02-17, status=1, ipAttribution=)]
    2012-02-17 yese

    #默沙东#

    0